Ardelyx (ARDX) Operating Expenses (2013 - 2026)
Ardelyx's (ARDX) quarterly Operating Expenses came in at $127.3 million in Q1 2026, up 15.21% YoY from $110.5 million in Q1 2025, and down 14.47% on a QoQ basis from $148.8 million in Q4 2025.
Ardelyx (ARDX) Operating Expenses (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Operating Expenses data on file, last reported at $127.3 million in Q1 2026.
- Quarterly Operating Expenses rose 15.21% year-over-year to $127.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $477.4 million (up 16.88% YoY) and the FY2025 annual result came in at $448.3 million, up 23.99% from the prior year.
- Operating Expenses declined to $127.3 million in Q1 2026, from $148.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $148.8 million in Q4 2025 to a low of $26.1 million in Q3 2022.
- A 5-year average of $73.5 million and a median of $75.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses sank 39.8% — and 2023, when it surged 159.99%.
- Tracing ARDX's Operating Expenses over 5 years: stood at $28.9 million in 2022, then surged by 159.99% to $75.1 million in 2023, then jumped by 86.89% to $140.3 million in 2024, then climbed by 6.06% to $148.8 million in 2025, then dropped by 14.47% to $127.3 million in 2026.
- The last three Operating Expenses figures came in at $127.3 million (Q1 2026), $148.8 million (Q4 2025), and $101.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 133.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.30 Mn |
| Mar 31, 2026 | 127.27 Mn |
| Dec 31, 2025 | 148.80 Mn |
| Sep 30, 2025 | 101.68 Mn |
| Jun 30, 2025 | 99.65 Mn |
| Mar 31, 2025 | 110.46 Mn |
| Dec 31, 2024 | 140.30 Mn |
| Sep 30, 2024 | 80.28 Mn |
| Jun 30, 2024 | 77.42 Mn |
| Mar 31, 2024 | 63.57 Mn |
| Dec 31, 2023 | 75.07 Mn |
| Sep 30, 2023 | 41.30 Mn |
| Jun 30, 2023 | 35.47 Mn |
| Mar 31, 2023 | 35.90 Mn |
| Dec 31, 2022 | 28.87 Mn |
| Sep 30, 2022 | 26.13 Mn |
| Jun 30, 2022 | 28.60 Mn |
| Mar 31, 2022 | 28.28 Mn |
| Dec 31, 2021 | 35.30 Mn |
| Sep 30, 2021 | 43.41 Mn |